Boosting the antimicrobial performance based on new fused spirothiazolidine framework analogs
Walaa I. El-Sofany, Eman M. Flefel, Osama M. Darwesh, Mahmoud El‐Shahat
Abstract
Abstract New spiro[cyclohexane-1,2'-thiazolo[4,5- b ]pyridine derivatives ( 3 – 23 ) were investigated. Then there is in vitro antimicrobial potency against possible organisms Staphylococcus aurous ATCC-47,077, Bacillus cereus ATCC-12228, Escherichia coli ATCC-25922, Salmonella typhi ATCC-15566, and Candida albicans ATCC-10231 were tested utilizing commercially available antibiotics ampicillin as a reference drug. A preliminary antimicrobial test represented that derivatives: (Aldoses) 3'-(4-fluorophenyl)-5'-(methyleneamino)-7'-( p -tolyl)- 3'H -spiro[cyclohexane-1,2'-thiazolo[4,5-b]pyridine]-6'-carbonitrile ( 16–19 ) and (Acetyl aldoses) 3'-(4-fluorophenyl)-5'-(methyleneamino)-7'-( p -tolyl)- 3'H -spiro [cyclohexane-1,2'-thiazolo[4,5-b]pyridine]-6'-carbonitrile ( 20–23 ) exhibited higher antifungal, and antibacterial performance with minimum inhibitory concentrations values of (39–67 µg/ml) toward all pathogenic strains compared to common reference drug ampicillin.